Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-3-8
pubmed:abstractText
Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow-hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-10468869, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-12370282, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-12433676, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-12606179, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-14897912, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-15486069, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-15514116, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-15671438, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-15797999, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-15886319, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-16497104, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-16769583, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-16882706, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-16939499, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-1705834, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-17229910, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-17318417, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-17721544, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-18023212, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-18689548, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-19047680, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-19212416, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-19264680, http://linkedlifedata.com/resource/pubmed/commentcorrection/19833632-9672759
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1592-8721
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
505-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.
pubmed:affiliation
Renal Medicine, Imperial College London, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. d.ashby@imperial.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't